
Please try another search
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Name | Age | Since | Title |
---|---|---|---|
Andrew Cheng | 57 | 2017 | Independent Director |
Beth C. Seidenberg | 68 | 2016 | Independent Director |
Scott William Morrison | 67 | 2020 | Independent Director |
Patrick Gerald Enright | 64 | 2020 | Independent Director |
Maha Mehdi Katabi | 52 | 2020 | Independent Director |
Marshall W. Fordyce | 50 | 2016 | Founder, President, CEO & Director |
Michael M. Morrissey | 64 | 2022 | Independent Chairman of the Board |
Kimball Hall | 58 | 2021 | Independent Director |
Christy J. Oliger | 55 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review